11:20 AM EDT, 03/31/2025 (MT Newswires) -- CERo Therapeutics ( CERO ) said Monday the US Food and Drug Administration has cleared its second investigational new drug application for CER-1236 for a phase 1 trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.

"Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors," said Chief Medical Officer Robert Sikorski. AML refers to acute myeloid leukemia.

The company said that recent results showed that CER-1236 treated ovarian cancer cells and didn't generate toxicity in mice.

Price: 0.76, Change: +0.01, Percent Change: +1.20